MK1084-012: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Principal Investigator
Daboul, Nour
Phase
III
Age Group
Adult
Applicable Disease Sites
Gastrointestinal Cancers
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Meg Zafiris
Research Specialist
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.